Luc Bauchet

Dr. Luc Bauchet


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2010 in Neuro-Oncology
Verified
Journal Article
Closed access
LBLuc Bauchet
Luc Bauchet
HMH. Mathieu-Daude
H. Mathieu-Daude
PFP. Fabbro-Peray
P. Fabbro-Peray
VRV. Rigau
V. Rigau
MFM. Fabbro
M. Fabbro
JHJ. Honnorat
J. Honnorat
This report, an audit requested by the French government, describes oncological patterns of care, prognostic factors, and survival for patients with newly diagnosed and histologically confirmed glioblastoma multiforme (GBM) in France. The French Brain Tumor DataBase, which is a national multidisciplinary (neurosurgeons, neuropathologists, radiotherapists, neurooncologists, epidemiologists, and biostatisticians) network, prospectively collected initial data for the cases of GBM in 2004, and a specific data card was used to retrospectively collect data on the management and follow-up care of these patients between January 1, 2004, and December 1, 2006. We recorded 952 cases of GBM (male/female ratio 1.6, median age 63.9 years, mean preoperative Karnofsky performance status [KPS] 79). Surgery consisted of resection (RS; n = 541) and biopsy (n = 411); 180 patients did not have subsequent oncological treatment. After surgery, first-line treatment (n = 772) consisted of radiotherapy (RT) and temozolomide (TMZ) concomitant +/- adjuvant in 314 patients, RT alone in 236 patients, chemotherapy (CT) alone in 157 patients, and other treatment modalities in 65 patients. Median overall survival was 286 days (95% CI, 266-314) and was significantly affected by age, KPS, and tumor location. Median survival (days, 95% CI) associated with these main strategies, when analyzed by a surgical group, were as follows: RS + RT-TMZ((n=224)): 476 (441-506), biopsy + RT-TMZ((n=90)): 329 (301-413), RS + RT((n=147)): 363 (331-431), biopsy + RT((n=89)): 178 (153-237), RS + CT((n=61)): 245 (190-361), biopsy + CT((n=96)): 244 (198-280), and biopsy only((n=118)): 55 (46-71). This study illustrates the usefulness of a national brain tumor database. To our knowledge, this work is the largest report of recent GBM management in Europe.

13 April 2007 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
LBLuc Bauchet
Luc Bauchet
VRValérie Rigau
Valérie Rigau
HMHélène Mathieu-Daudé
Hélène Mathieu-Daudé
DFDominique Figarella-Branger
Dominique Figarella-Branger
DHDelphine Hugues
Delphine Hugues
FSFrançois Segnarbieux
François Segnarbieux

20 November 2008 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
LBLuc Bauchet
Luc Bauchet
VRValérie Rigau
Valérie Rigau
HMHélène Mathieu-Daudé
Hélène Mathieu-Daudé
PFPascale Fabbro-Peray
Pascale Fabbro-Peray
GPGilles Palenzuela
Gilles Palenzuela
AFAssociation des Neuro-Oncologues d’Expression Française
Association des Neuro-Oncologues d’Expression Française

6 December 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
PFPascale Fabbro-Peray
Pascale Fabbro-Peray
SZSonia Zouaoui
Sonia Zouaoui
ADAmélie Darlix
Amélie Darlix
MFMichel Fabbro
Michel Fabbro
JPJohan Pallud
Johan Pallud
LBLuc Bauchet
Luc Bauchet
Background Glioblastoma is the most frequent primary malignant brain tumor. In daily practice and at whole country level, oncological care management for glioblastoma patients is not completely known. Objectives To describe oncological patterns of care, prognostic factors, and survival for all patients in France with newly-diagnosed and histologically confirmed glioblastoma, and evaluate the impact of extended temozolomide use at the population level. Methods Nationwide population-based cohort study including all patients with newly-diagnosed and histologically confirmed glioblastoma in France in 2008 and followed until 2015. Results Data from 2053 glioblastoma patients were analyzed (male/female ratio 1.5, median age 64 years). Median overall survival (OS) was 11.2 [95% confidence interval (CI) 10.7–11.9] months. The first-line therapy and corresponding median survival (MS, in months) were: 13% did not receive any oncological treatment (biopsy only) (MS = 1.8, 95% CI 1.6–2.1), 27% received treatment without the combination of radiotherapy (RT)–temozolomide (MS = 5.9, 95% CI 5.5–6.6), 60% received treatment including the initiation of the concomitant phase of RT–temozolomide (MS = 16.4, 95% CI 15.2–17.4) whom 44% of patients initiated the temozolomide adjuvant phase (MS = 18.9, 95% CI 18.0–19.8). Only 22% patients received 6 cycles or more of adjuvant temozolomide (MS = 25.5, 95% CI 24.0–28.3). The multivariate analysis showed that the risk of mortality was significantly higher for the non-progressive patients who stopped at 6 cycles (standard protocol) than those who continued the treatment, hazard ratio = 1.5 (95% CI 1.2–1.9). Conclusion In non-progressive patients, prolonging the adjuvant temozolomide beyond 6 cycles may improve OS.

14 June 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
JNJean NAKHLE
Jean NAKHLE
KKKhattar Khattar
Khattar Khattar
TÖTülin Özkan
Tülin Özkan
ABAdel Boughlita
Adel Boughlita
DMDaouda ABBA MOUSSA
Daouda ABBA MOUSSA
MVMarie-Luce VIGNAIS
Marie-Luce VIGNAIS
Glioblastomas (GBM) are heterogeneous tumors with high metabolic plasticity. Their poor prognosis is linked to the presence of glioblastoma stem cells (GSC), which support resistance to therapy, notably to temozolomide (TMZ). Mesenchymal stem cells (MSC) recruitment to GBM contributes to GSC chemoresistance, by mechanisms still poorly understood. Here, we provide evidence that MSCs transfer mitochondria to GSCs through tunneling nanotubes, which enhances GSCs resistance to TMZ. More precisely, our metabolomics analyses reveal that MSC mitochondria induce GSCs metabolic reprograming, with a nutrient shift from glucose to glutamine, a rewiring of the tricarboxylic acid cycle from glutaminolysis to reductive carboxylation and increase in orotate turnover as well as in pyrimidine and purine synthesis. Metabolomics analysis of GBM patient tissues at relapse after TMZ treatment documents increased concentrations of AMP, CMP, GMP, and UMP nucleotides and thus corroborate our in vitro analyses. Finally, we provide a mechanism whereby mitochondrial transfer from MSCs to GSCs contributes to GBM resistance to TMZ therapy, by demonstrating that inhibition of orotate production by Brequinar (BRQ) restores TMZ sensitivity in GSCs with acquired mitochondria. Altogether, these results identify a mechanism for GBM resistance to TMZ and reveal a metabolic dependency of chemoresistant GBM following the acquisition of exogenous mitochondria, which opens therapeutic perspectives based on synthetic lethality between TMZ and BRQ.Significance: Mitochondria acquired from MSCs enhance the chemoresistance of GBMs. The discovery that they also generate metabolic vulnerability in GSCs paves the way for novel therapeutic approaches.

1 March 2018 in Neurochirurgie
Verified
Journal Article
Closed access
SZS. Zouaoui
S. Zouaoui
ADA. Darlix
A. Darlix
VRV. Rigau
V. Rigau
HMH. Mathieu-Daudé
H. Mathieu-Daudé
FBF. Bauchet
F. Bauchet
LBLuc Bauchet
Luc Bauchet